Drug
Ly3023414
Ly3023414: highest development phase Phase 2, developed by Eli Lilly. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| LY3023414 NCT02407054 | Phase 2 | Prostate Cancer Metastatic |
| LY3023414 NCT02443337 | Phase 2 | Non-small Cell Lung Cancer Metastatic |
Latest
No recent events.
Follow Ly3023414 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.